Brought to you by 
Series A round lands $12mm for ACT Biotech
May 2008
Executive Summary
ACT Biotech (small-molecule therapeutics for cancer) raised $12mm through the first tranche of its Series A round led by NGN Capital. The company expects to bring in a total of $20mm after closing the subsequent round, planned for later this year.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A round lands $12mm for ACT Biotech
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice